What is it about?
The HIV-1 reverse transcriptase mutation I132M, which confers high-level resistance to the nonnucleoside RT inhibitors (NNRTIs) nevirapine and delavirdine, is hypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir (TNV). The replication capacity of I132M HIV-1 is severely impaired, but could be partially or completely compensated by an additional RT mutation (A62V or L214I). These results probably accounts for the infrequent selection of I132M in patients who are failing NNRTI-containing therapy. Also, the single I132M mutation, which is outside of the polymerase active site and inside of the p51 subunit of RT, can significantly influence nucleotide selectivity.
Featured Image
Read the Original
This page is a summary of: The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs, Journal of Virology, February 2009, ASM Journals,
DOI: 10.1128/jvi.01968-08.
You can read the full text:
Contributors
The following have contributed to this page
